Kinaset Therapeutics key facts
as of Oct 2026- Developer of respiratory drugs designed for novel therapeutics for patients affected by intractable diseases.
- Kinaset Therapeutics is valued at approximately $186.0M as of Oct 2026, set at its later-stage round, Jan 2026; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $143.0M across 3 recorded rounds; the latest was Later Stage VC (Series B) ($103.0M) in Jan 2026.
- Notable investors include RA Capital Management, SV Health Investors, EQT Life Sciences, Schroders Capital, Vivo Capital — 12 tracked in total.
- Kinaset Therapeutics has filed 3 Form Ds with the SEC since 2020, most recently Jul 2023 ($28.5M sold to 3 investors).
- Status: Privately Held (backing).
Valued at $186.0M at its later-stage round, Jan 2026. Nothing has traded since.
- ·The complete investor list: 12 names
- ·Watch Kinaset Therapeutics: the Monday email on marks, rounds and moves
Kinaset Therapeutics funding rounds
3 roundsWho backs Kinaset Therapeutics
12+Kinaset Therapeutics valuation
Kinaset Therapeutics was valued at $186 million at its later-stage round in Jan 2026. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has Kinaset Therapeutics raised?
Kinaset Therapeutics has raised $143 million across 3 recorded rounds since 2020. The largest was a $28.5 million early-stage round in Jul 2022; the most recent was a $103 million Series B in Jan 2026.
Kinaset Therapeutics has filed 3 Form Ds with the SEC since 2020, most recently in Jul 2023 ($28.5 million sold to 3 investors).
Kinaset Therapeutics investors
12 investors are on record for Kinaset Therapeutics, including RA Capital Management, SV Health Investors, EQT Life Sciences and Schroders Capital. By type, the record holds 3 venture capital firms and 2 asset managers. The Series B in Jan 2026 drew 11 investors.
Comparable companies
Comparable drug discovery names by valuation on PrivateMarketView: Plexium ($200 million), Ajax Therapeutics ($193 million) and Cambrian Bio ($180 million).
About Kinaset Therapeutics
Developer of respiratory drugs designed for novel therapeutics for patients affected by intractable diseases. The company develops inhaled therapeutics to address significant unmet medical needs in respiratory diseases, enabling healthcare providers with a less invasive and cost-effective alternative for treating severe asthma.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Medfield, MA, United States
- Founded
- 2020
- Employees
- 9
- Website
- kinasettherapeutics.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.